This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/04/2026
In the QUASAR clinical program and open-label LTE, no cases of active TB were reported in patients receiving TREMFYA through week 140.8-10
In the ASTRO clinical study, no cases of active TB were reported through week 24.12
| Pooled IBD | ||||
|---|---|---|---|---|
| Induction Period (Weeks 0-12)a | Through 1 year | |||
| Placebo (n=743) | TREMFYA (n=1703) | Placebob | TREMFYAc (n=2057) | |
| Total PYs of follow-up | 171.6 | 399.9 | 447.4 | 1752.1 |
| Events/100 PY (95% CI)d | ||||
| Active TB | 0.00 (0.00, 1.75) | 0.00 (0.00, 0.75) | 0.00 (0.00, 0.67) | 0.06 (0.00, 0.32) |
| Abbreviations: CI, confidence interval; IBD, inflammatory bowel disease; PY, participant-years; TB, tuberculosis.Note: Includes all patients who were treated.Note: Patients are counted only once for any given event, regardless of the number of times they actually experienced the event. Adverse events are coded using MedDRA version 26.aUlcerative colitis: (0-12 weeks) CNTO1959UCO3001 QUASAR Induction Study 1 and Induction Study 2 (VEGA not included due to no PBO control); Crohn's disease (0-12 weeks): CNTO1959CRD3001 GALAXI 1, GALAXI 2, GALAXI 3 and CNTO1959CRD3004 GRAVITI. bUlcerative colitis: includes data up to the first dose of TREMFYA for participants who were initially treated with placebo; includes data at or after 12 weeks from the last induction dose of TREMFYA for participants who were treated with TREMFYA in induction and were rerandomized to placebo in the maintenance study, up to the dose adjustment for participants who had a dose adjustment. Crohn's disease: includes data up to the time of rescue or crossover. cUlcerative colitis: CNTO1959UCO3001 QUASAR (through induction week 20 for participants who did not enter the maintenance study and did not receive treatment at induction week 12; through induction Week 32 for participants who did not enter the maintenance study and received treatment at induction week 12; through maintenance week 44 for participants who entered the maintenance study); CNTO1959UCO2002 VEGA through week 38 (TREMFYA monotherapy arm only); includes all TREMFYA data and data up to 12 weeks from the last induction dose of TREMFYA for participants who were randomized to placebo in the maintenance study. Crohn's disease: CNTO1959CRD3001 GALAXI 1, GALAXI 2 and GALAXI 3, and CNTO1959CRD3004 GRAVITI through week 48; includes data from the first dose of TREMFYA onward for participants who were rescued or crossed over from placebo. dConfidence interval based on an exact method assuming that the observed number of events follows a Poisson distribution. | ||||
Faye et al (2026)14 analyzed pooled safety data of TREMFYA from 14 phase 2/3 studies up to 1 year in CD, UC and psoriatic diseases in patients aged ≥60 years old. Summarized below are results specific to patients with CD or UC.
A literature search of MEDLINE®
| 1 | Data on File. Guselkumab Company Core Data Sheet (CCDS) v022. Janssen Research & Development, LLC. EDMS-ERI-111962822; 2025. |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 |
Would you like to clear and leave your conversation? Message history will be lost.